GILD, ROIV win FDA nod in weekly biotech buzz
Weekly Buzz highlights FDA nods for GILD and ROIV; also cites a BHVN/LLY deal and SYRE missing a monotherapy goal.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.